MDT

99.8

-0.46%↓

A

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

A

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

A

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

A

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

A

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

Search

PerkinElmer Inc

Open

SectorHealthcare

0

Overview

Share price change

24h

Current

Min

Max

Key metrics

By Trading Economics

Income

-8.6M

47M

Sales

-21M

699M

P/E

Sector Avg

52.608

87.826

EPS

0.4

Dividend yield

0.29

Profit margin

6.675

Employees

11,000

EBITDA

-14M

181M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+7.66% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.29%

2.26%

Next Earnings

30 sty 2026

Next Dividend date

6 lut 2026

Next Ex Dividend date

16 sty 2026

Market Stats

By TradingEconomics

Market Cap

569M

12B

Previous open

0

Previous close

0

News Sentiment

By Acuity

34%

66%

106 / 372 Ranking in Healthcare

PerkinElmer Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 sty 2026, 23:11 UTC

Earnings

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

7 sty 2026, 22:55 UTC

Major Market Movers

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

7 sty 2026, 21:39 UTC

Major Market Movers

Raytheon Down Following Trump Post Criticizing Company

7 sty 2026, 20:13 UTC

Major Market Movers

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

7 sty 2026, 20:03 UTC

Major Market Movers

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

7 sty 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 sty 2026, 23:46 UTC

Market Talk

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

7 sty 2026, 23:42 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

7 sty 2026, 23:34 UTC

Market Talk

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

7 sty 2026, 23:29 UTC

Acquisitions, Mergers, Takeovers

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

7 sty 2026, 22:48 UTC

Market Talk

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

7 sty 2026, 22:46 UTC

Earnings

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

7 sty 2026, 22:45 UTC

Earnings

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

7 sty 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Revolution Medicines Draws Takeover Interest -- 2nd Update

7 sty 2026, 22:42 UTC

Earnings

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

7 sty 2026, 22:41 UTC

Earnings

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

7 sty 2026, 22:41 UTC

Earnings

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

7 sty 2026, 22:40 UTC

Major Market Movers

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

7 sty 2026, 22:31 UTC

Market Talk

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

7 sty 2026, 22:22 UTC

Market Talk

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

7 sty 2026, 22:01 UTC

Market Talk

Valuations of New Zealand Property Stocks Supportive -- Market Talk

7 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 sty 2026, 21:46 UTC

Market Talk

Northern Star's Revised Guidance Looks Achievable -- Market Talk

7 sty 2026, 21:22 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

7 sty 2026, 21:18 UTC

Acquisitions, Mergers, Takeovers

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

7 sty 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

7 sty 2026, 20:29 UTC

Acquisitions, Mergers, Takeovers

AbbVie Near Deal for Revolution Medicines -- Update

7 sty 2026, 20:27 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

7 sty 2026, 19:58 UTC

Market Talk

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

7 sty 2026, 19:48 UTC

Major Market Movers

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Peer Comparison

Price change

PerkinElmer Inc Forecast

Price Target

By TipRanks

7.66% upside

12 Months Forecast

Average 110.88 USD  7.66%

High 123 USD

Low 100 USD

Based on 11 Wall Street analysts offering 12 month price targets forPerkinElmer Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

6

Buy

5

Hold

0

Sell

Sentiment

By Acuity

106 / 372 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat